Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out

Search

  • Advanced search
The Journal of Immunology
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons
  • Subscribe
  • My alerts
  • Log in
  • Log out
The Journal of Immunology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Follow The Journal of Immunology on Twitter
  • Follow The Journal of Immunology on RSS

Human Lupus Serum Induces Neutrophil-Mediated Organ Damage in Mice That Is Enabled by Mac-1 Deficiency

Florencia Rosetti, Naotake Tsuboi, Kan Chen, Hiroshi Nishi, Thomas Ernandez, Sanjeev Sethi, Kevin Croce, George Stavrakis, Jorge Alcocer-Varela, Diana Gómez-Martin, Nico van Rooijen, Vasileios C. Kyttaris, Andrew H. Lichtman, George C. Tsokos and Tanya N. Mayadas
J Immunol October 1, 2012, 189 (7) 3714-3723; DOI: https://doi.org/10.4049/jimmunol.1201594
Florencia Rosetti
*Department of Pathology, Center for Excellence in Vascular Biology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115;
†Immunology Graduate Program, Division of Medical Sciences, Harvard Graduate School of Arts and Sciences at Harvard Medical School, Boston, MA 02115;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Naotake Tsuboi
*Department of Pathology, Center for Excellence in Vascular Biology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kan Chen
*Department of Pathology, Center for Excellence in Vascular Biology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiroshi Nishi
*Department of Pathology, Center for Excellence in Vascular Biology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Ernandez
*Department of Pathology, Center for Excellence in Vascular Biology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sanjeev Sethi
‡Division of Anatomic Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin Croce
§Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02115;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George Stavrakis
*Department of Pathology, Center for Excellence in Vascular Biology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jorge Alcocer-Varela
¶Departamento de Inmunología y Reumatología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City 1400, Mexico;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Diana Gómez-Martin
¶Departamento de Inmunología y Reumatología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City 1400, Mexico;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nico van Rooijen
‖Department of Molecular Cell Biology, Vrije University Medical Center, 1081 Amsterdam, The Netherlands; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vasileios C. Kyttaris
#Division of Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew H. Lichtman
*Department of Pathology, Center for Excellence in Vascular Biology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George C. Tsokos
#Division of Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tanya N. Mayadas
*Department of Pathology, Center for Excellence in Vascular Biology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF + SI
  • PDF
Loading

Abstract

Systemic lupus erythematosus (SLE) is a chronic, multiorgan inflammatory autoimmune disorder associated with high levels of circulating autoantibodies and immune complexes. We report that passive transfer of human SLE sera into mice expressing the uniquely human FcγRIIA and FcγRIIIB on neutrophils induces lupus nephritis and in some cases arthritis only when the mice additionally lack the CD18 integrin, Mac-1. The prevailing view is that Mac-1 on macrophages is responsible for immune complex clearance. However, disease permitted by the absence of Mac-1 is not related to enhanced renal immune complex deposition or in situ C1q/C3 complement activation and proceeds even in the absence of macrophages. Instead, disease is associated with increased FcγRIIA-induced neutrophil accumulation that is enabled by Mac-1 deficiency. Intravital microscopy in the cremasteric vasculature reveals that Mac-1 mitigates FcγRIIA-dependent neutrophil recruitment in response to deposited immune complexes. Our results provide direct evidence that human SLE immune complexes are pathogenic, demonstrate that neutrophils are primary mediators of end organ damage in a novel humanized lupus mouse model, and identify Mac-1 regulation of FcγRIIA-mediated neutrophil recruitment as a key step in development of target organ damage.

Introduction

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that affects multiple organs, including the kidney, joints, and skin, with development of nephritis being one of the most serious complications of this disorder. SLE is characterized by a loss of tolerance to self-Ags and high titers of circulating autoantibodies (1). In mice, deletion of the common Fcγ-chain (γ−/−) that results in the loss of activating FcγRs protects lupus-prone New Zealand Black/New Zealand White mice from spontaneously developing lupus nephritis (2, 3). Yet there is little direct evidence that immune complexes (ICs) are causative, as there are no reports that the passive transfer of SLE sera reproduces disease. Moreover, autoantibodies to classical lupus Ags such as dsDNA are not sufficient for development of nephritis in lupus-prone mouse strains, and renal biopsies of SLE patients without clinically evident nephritis can exhibit IC deposition. Thus, factors in addition to ICs most likely dictate the propensity to develop target organ damage, the identification of which remains a central question in the field (4–6).

Human genome-wide association studies have shown that small variations in a large number of genes are associated with lupus. The current paradigm assumes that these traits modulate, through different pathways, the expression of disease in lupus. Variations in one of these genes is the leukocyte integrin Mac-1 (ITGAM, CD11b/CD18) (7), a member of the leukocyte CD18 integrin family of adhesion molecules that are obligate heterodimers of unique CD11 subunits paired with a common CD18 chain. Mac-1 has multiple ligands, including complement fragment C3bi and ICAM-1 on the endothelium (8), and the Mac-1 R77H polymorphism associated with lupus (9) leads to a reduction in its binding to both these ligands (10). The question remains as to whether Mac-1, which typically promotes inflammation and host defense (8), plays a role in the pathogenesis of lupus. The prevailing view is that Mac-1 on macrophages clears circulating ICs (9), although there is no direct evidence of this. Likewise, polymorphisms in human FcγRIIA and FcγRIIIB are associated with lupus through mechanisms that remain largely unclear (7). The physiological roles of the uniquely human neutrophil FcγRs, which structurally differ from their mouse counterparts (11, 12), have been addressed in genetically engineered mice. Expression of the single polypeptide FcγRIIA, containing an ITAM, and the GPI-anchored FcγRIIIB selectively on neutrophils of Fcγ-chain–deficient mice (IIA+γ−/−, IIA+IIIB+γ−/−) restored susceptibility of γ−/− animals to progressive anti-glomerular basement membrane (GBM) nephritis and K/B×N serum-induced arthritis (13, 14). Although both human FcγRs promoted neutrophil accumulation, only FcγRIIA alone induced tissue injury most likely through its established ability to promote neutrophil cytotoxic functions (13).

Difficulty in understanding the underlying mechanisms of SLE arises from the multifactorial influences on disease course, including environmental, infectious, and hormonal factors, the association of lupus with abnormalities at all levels of the immune system, and the clinical heterogeneity of the disease (7). The disparate disease courses in SLE most likely converge into a common route of end organ damage. In this study, in a new model of lupus induced by the passive transfer of human SLE sera, we provide direct evidence that SLE ICs are pathogenic, show a central role for neutrophils in target organ damage, and demonstrate that two molecules, FcγRIIA and Mac-1, determine the capacity of ICs to cause tissue damage. In addition, these results, coupled with the analysis of neutrophil behavior by intravital microscopy, revealed a new regulatory role for Mac-1 in FcγRIIA-mediated neutrophil recruitment following deposition of circulating ICs.

Materials and Methods

Mice

Fcγ-chain–deficient mice, human FcγRIIA and FcγRIIIB-expressing γ-chain–deficient mice (IIA+γ−/− or IIA+IIIB+γ−/−), Mac-1–deficient mice (Mac-1−/−), and CD18-deficient mice (CD18−/−) were as described (13, 15–17). Mac-1–deficient mice were bred with IIA+γ−/− or IIA+IIIB+γ−/− mice to generate IIA+γ−/−Mac-1−/− and IIA+IIIB+γ−/−Mac-1−/− animals or with wild-type (WT) mice to generate IIA+γ+/+Mac-1−/− and IIA+γ+/+ mice. Mice were bred in a specific pathogen-free facility. Age- and gender-matched mice 8–12 wk old were used in all experiments. The Harvard Medical School Animal Care and Use Committee approved all procedures used in this study.

Passive transfer of human SLE sera or rabbit anti-GBM Ab

For the human SLE sera transfer model, mice were injected s.c. in both flanks with 2.5 μg human IgG (Jackson ImmunoResearch Laboratories) in CFA (Thermo Scientific and Difco) on day −3. On days 0 and 2, 200 μl sterile serum was injected i.v. For induction of nephrotoxic nephritis, mice were given rabbit IgG in CFA at day −3 in the footpad and rabbit αGBM antisera at day 0, as described (18), and urine and kidneys were collected at day 21.

Human sera samples

Human serum samples were obtained from the Lupus Clinic at the Beth Israel Deaconess Medical Center or Instituto Nacional de Ciencias Medicas y de la Nutricion Salvador Zubiran. Patients with SLE were diagnosed according to the classification criteria of the American College of Rheumatology. The inclusion criteria for SLE patients were patients who fulfilled ≥4 of 11 American College of Rheumatology criteria for SLE and at the time of the first blood draw had active disease (i.e., SLE disease activity index ≥6) and were diagnosed with nephritis. Normal serum was obtained from healthy individuals matched for age, gender, and ethnicity. At the time of serum collection, all individuals showed no signs or symptoms of infection. Informed consent was obtained from all patients and healthy donors under a Beth Israel Deaconess Medical Center Institutional Review Board-approved protocol. Unless indicated, all experiments were performed using serum from SLE patient A.

Disease evaluation

Functional assessment of renal damage.

Spot urine samples were collected, and urine albumin and creatinine were evaluated by ELISA (Bethyl Laboratories) and a chemical assay (Cayman Chemical), respectively (13), and expressed as a ratio of urine albumin to creatinine.

Clinical scoring of arthritis.

Mice were evaluated every other day after induction of disease. Inflammation of each limb was scored, as reported previously (19): 0, no evident inflammation; 1, redness or swelling of 1 toe; 2, redness or swelling of >1 toe; 3, ankle or tarsal-metatarsal involvement; 4, redness or swelling of the entire paw.

Histological assessment of tissue injury.

Tissue sections were blindly evaluated. Histological score included endocapillary proliferation, leukocyte infiltration, and crescents, as previously described (20). For joint lesions, histological scores reflected leukocyte infiltration, synovial thickening, and cartilage and bone erosion.

Histological studies

Kidneys were fixed in formalin and paraffin embedded, or frozen in OCT medium, and 5-μm sections were prepared. Toe specimens were fixed in 4% paraformaldehyde and decalcified with modified Kristensen’s solution. After dehydration, the tissues were embedded in paraffin and 5-μm sections were made (21).

Immunohistochemistry.

For kidneys, periodic acid-Schiff, H&E, and dichloroacetate esterase (to identify neutrophils) on paraffin-embedded sections were performed, as described (22). Neutrophils in 100 glomerular cross-sections were quantified and presented as neutrophils per glomerular cross-section. Immunohistochemistry on frozen sections was performed using a two-layer peroxidase method. Sections were immunostained with anti-F4/80 for macrophages (BioLegend), anti-CD3 (Serotech) for T cells, and anti-C1q (Hycult Biotech) for C1q deposition, and counterstained with Gill Hematoxylin No. 2 (NewComerSupply). Tissue area occupied by macrophages or glomerular C1q deposition in four ×20 consecutive fields was quantified using ImagePro. Sections of paraffin-embedded toes were stained with H&E, and immunohistochemistry was performed with anti–NIMP-R14 (Abcam) for neutrophil quantification, anti-F4/80 (BioLegend) for macrophages, anti-CD3 (Serotech) for T cells, or anti-human IgG (Invitrogen). The total number of neutrophils in a toe cross-section was counted and divided by the total tissue area in each section, using ImagePro.

Immunofluorescence.

Human and mouse IgG deposition were evaluated on frozen sections using anti-human IgG or anti-mouse IgG (Invitrogen) Alexa fluor 488-conjugated Abs, respectively. Deposition of C3 was evaluated using a FITC-conjugated anti-C3 Ab (ICN/CAPPEL). Images of at least 15 glomeruli per mouse were captured, and glomerular fluorescence intensity was measured using the acquisition and analysis software Metamorph (Molecular Devices). To evaluate human IgG subclasses, immunofluorescence was performed using anti-human IgG1, IgG2, IgG3, and IgG4 Abs (The Binding Site), followed by an anti-sheep DyLight-488–conjugated Ab (Jackson ImmunoResearch Laboratories).

Electron microscopy.

Kidney samples were taken 10 d after injection of SLE sera and processed using standard techniques.

Generation of a K562 stable cell line and analysis of binding to ICAM-1

The R77H mutation was introduced into human CD11b DNA by standard PCR techniques. K562 cells were transfected with WT or mutant (R77H) CD11b and CD18 plasmids by electroporation and confirmed by sequencing. Single-cell sorting was used to select CD11b-positive cells. Cells were cultured in RPMI 1640 media supplemented with 10% heat-inactivated FBS, under constant selection using G418 (500 μg/ml; Invivogen). CD11b expression was assessed by FACS analysis using anti-human CD11b-PE–labeled Ab (BD Pharmingen). To evaluate K562 cell binding to ICAM-1-Fc, cells were preactivated with 1 mM MnCl2 for 10 min in HEPES buffer and drawn across a coverslip containing immobilized ICAM-1-Fc (15 μg/ml; R&D Systems) under 0.1 dynes/cm2 shear flow. The number of cells bound in four different fields was quantified every 2 min over a 10-min period.

IgG depletion and quantification of human IgG

SLE serum was incubated with protein A/G-coated agarose beads (Thermo Scientific) or control agarose beads. Depletion was determined by measuring human IgG by ELISA (Bethyl Laboratories). Human ICs were quantified in human and mouse serum using an ELISA kit with C1q as the capture element (ALPCO Immunoassays). Due to cross-reactivity with mouse IgG, an anti-human HRP Ab (Bethyl Laboratories) was used as the secondary Ab for the quantification of human ICs in murine serum samples.

Macrophage depletion using clodronate liposomes

Mice were given an i.p. injection of 500 μl liposomes containing clodronate or PBS (23) on day −5 before the first SLE injection, followed by 200 μl every 5 d. Tissue was harvested at day 10 or 14 after SLE sera injection. Macrophage depletion was confirmed by immunohistochemistry of kidneys and spleen using anti-F4/80 Ab.

Intravital microscopy evaluation of reverse passive Arthus reaction in the cremaster muscle

Rabbit IgG anti-BSA Ab (200 μg/300 μl; Sigma-Aldrich, St. Louis, MO) was injected intrascrotally, followed by an i.v. injection of BSA (300 μg/100 μl; Sigma-Aldrich). After 3 h, leukocyte recruitment in the cremaster of anesthetized mice was evaluated by intravital microscopy, as previously described (13). Four venules per mouse were analyzed. Leukocyte rolling velocities were measured by tracking single leukocytes (10/venule) over several frames and calculating the distance moved per unit time (μm/s). Adherent leukocytes were defined as cells remaining stationary for 30 s and were expressed as the number of cells/mm2 venule.

MIP-2 was locally applied, as previously described (24). Briefly, injections were done using a beveled glass pipette of 1 mm outer diameter mounted on a manual micromanipulator (MM-33; Warner Instruments, Hamden, CT). The tip was filled with 100 nmol/L MIP-2 (U.S. Biologicals). The pipette was placed, and the number of rollers across a perpendicular line and the number of adherent cells (Ab) in a 200-μm segment of the venule were recorded over a 1-min period. Next, air pressure was applied to the pipette, to trigger the injection of MIP-2 (<1 μl). Successful injection was verified by the presence of swelling of the interstitial tissue surrounding the pipette tip. The process of injection and the following minute were recorded. The number of cells that were adherent after MIP-2 injection (Aa) was evaluated. The Δ adherent cells, which is the percentage of rollers that adhered in response to MIP-2 injection, was calculated using the following equation: (Aa − Ab)/number of rollers × 100.

Statistical analysis

Data are expressed as mean ± SEM. For proteinuria data, the line represents the median of the group. Differences were determined by Mann-Whitney U test. For group analysis, one-way ANOVA was used for proteinuria data and two-way ANOVA was used for the cellular infiltration data. When significant differences were shown, data were subjected to Mann-Whitney U test or Bonferroni test, respectively, for comparison between two mouse strains. The p values <0.05 were considered significant.

Results

Human SLE serum induces nephritis in mice that express neutrophil human FcγRs and lack Mac-1

Human SLE serum was obtained from patients that had active disease (SLE disease activity index ≥6) and no clinical evidence of infection. Gender- and race-matched healthy individuals served as controls. Mice preimmunized with human IgG/CFA received two i.v. injections of SLE sera at days 0 and 2. Nephritis was monitored by analyzing albumin leakage in the urine over a 21-d period. SLE serum from patient A caused marked proteinuria in mice that expressed human FcγRs (hFcγRs) only when these mice additionally lacked Mac-1 (IIA+γ−/−Mac-1−/− and IIA+IIIB+γ−/−Mac-1−/−) (Fig. 1A). Proteinuria peaked at day 14 (Supplemental Fig. 1A). Mac-1–deficient mice expressing FcγRIIA alone, without FcγRIIIB, exhibited significant proteinuria, suggesting that this hFcγR was sufficient for disease development (Fig. 1A). No proteinuria was observed in Mac-1–sufficient mice expressing hFcγRs (IIA+γ−/− or IIA+IIIB+γ−/−), Mac-1–deficient mice without hFcγRs (γ+/+Mac-1−/−), or WT animals (Fig. 1A). Surface expression of human FcγRs and the sister CD18 integrin, LFA-1, was similar in Mac-1–deficient and sufficient groups (Supplemental Fig. 1B). Any effect of γ-chain deficiency superimposed on Mac-1 deficiency on disease susceptibility was ruled out as SLE serum induced nephritis in mice that express hFcγRIIA, lack Mac-1, and were γ-chain sufficient (Fig. 1B).

FIGURE 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1.

SLE sera induces nephritis in mice that express hFcγR and lack Mac-1. (A) Mice received two i.v. injections of SLE sera A on days 0 and 2, and urine albumin (normalized to creatinine) at day 14 was evaluated. The dashed line indicates the mean of proteinuria in mice not given SLE sera. Each data point represents one mouse, and the solid line is the median of the group. (B) Mice expressing the FcγRIIA in the presence of the γ-chain (IIA+γ+/+), and the same that are additionally Mac-1–deficient (IIA+γ+/+Mac-1−/−) were injected with SLE sera A and albuminuria was evaluated at days 7 and 14. Albuminuria in IIA+γ−/−Mac-1−/− mice given SLE sera was analyzed in parallel for comparison. Each dot represents one animal, and the line indicates the median of the group. ns, not significant. (C) Murine anti-human IgG was quantified in renal tissue by immunofluorescence in indicated transgenic mice that were untreated (Unt) or 21 d following SLE sera A transfer (SLE). WT mice given rabbit anti-GBM injection (WT αGBM) served as a positive control. Mean ± SEM are graphed. Dashed line is the average of pixel intensity in the Unt mice. (D) Representative images of renal sections (day 21) stained with H&E or periodic acid-Schiff (PAS). The arrow indicates a glomerular crescent that was observed in ∼5% of the glomeruli. A histological score was given, and mean ± SEM was graphed (n ≥ 5 mice per group). (E) Electron microscopy of glomeruli of mice given SLE sera: (i) IIA+IIIB+γ−/− mice had normal glomerular architecture; (ii and iv) IIA+IIIB+γ−/−Mac-1−/− mice exhibited mesangial expansion with increased cellularity (ii), neutrophils within capillary loops (iii) (×4,730), mesangial electron-dense deposits (*), and lysosomal vacuoles containing protein reabsorption droplets (arrows) (iv) typically observed during proteinuria (×11,100). *p < 0.05, **p < 0.01, ***p < 0.001. en, Endothelial; m, mesangial cell; n, neutrophils; p, podocyte.

Mouse anti-human IgG was detected in the serum (Supplemental Fig. 1C) and in the kidney (Fig. 1C) after SLE sera transfer, but this was much less compared with that in WT mice subjected to anti-GBM (nephrotoxic) nephritis (Fig. 1C), a widely used model of immune-mediated disease induced by preimmunization with rabbit IgG/CFA, followed by transfer of rabbit anti-GBM serum (25). Importantly, mouse anti-human IgG levels in both the serum and renal tissue were similar in disease-susceptible and nonsusceptible mice (Supplemental Fig. 1C, Fig. 1C). Although a role for mouse anti-human IgG and/or ICs formed from human IgG reacting with Ags in the mouse serum cannot be formally ruled out, it is unlikely to be critical for disease development for the following two reasons. First, SLE sera induced nephritis in the absence of preimmunization with CFA/human IgG (data not shown), albeit disease was more variable. Second, human FcγRs, and thus by inference human IgG, are required for development of nephritis. In the anti-GBM murine model, rabbit IgG triggers a robust murine anti-rabbit reaction; nonetheless, tissue injury is largely independent of the humoral response (26). We propose that, as is known for other autoimmune models, activation of the innate immune response by CFA in our SLE model may be important independent of the adaptive immune response (27).

Histopathological and electron microscopy analyses of renal tissue from human SLE sera-treated mice were undertaken. Congruent with proteinuria, glomerular damage and inflammation were observed only in hFcγR+γ−/−Mac-1−/− animals (Fig. 1D, 1E) and were associated with mesangial deposits of ICs (Fig. 1E). Together these data suggest that Mac-1 deficiency enables SLE-induced kidney damage. This may have relevance to human disease because the R77H polymorphism in the ITGAM gene (that encodes the CD11b chain of Mac-1) associated with SLE abrogates the capacity of Mac-1 expressed in a cell line, to bind its ligand ICAM-1 (Fig. 2).

FIGURE 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 2.

The SLE-associated R77H mutation of Mac-1 abrogates its capacity to bind ICAM-1 under shear flow. (A) Flow cytometry analysis of K562 cells stably expressing Mac-1 WT or Mac-1 R77H. Similar levels of Mac-1 were observed on the surface of Mac-1 WT and Mac-1 R77H-transfected cells. (B) Binding of K562 cells expressing WT or the R77H Mac-1 variant to plate-immobilized ICAM-1-Fc was evaluated under shear flow. Mac-1 R77H mutation prevented interaction with ICAM-1 compared with WT Mac-1. Mean ± SEM of four independent experiments is shown. **p < 0.01, ***p < 0.001.

Pathogenicity of SLE serum depends on the IgG fraction and its capacity to deposit in glomeruli

Sera collected from different SLE patients were tested in susceptible IIA+IIIB+γ−/−Mac-1−/− mice. Four of six SLE sera induced nephritis, whereas sera from five healthy controls (normal serum) or heat-aggregated human IgG (surrogate of ICs) failed to induce disease (Fig. 3A). Moreover, four of five sera from SLE patients at an independent clinical center induced nephritis compared with normal controls (Supplemental Fig. 1D). Notably, nephritis was observed with multiple SLE serum samples from the same patient when treatment and disease activity varied, but circulating ICs remained elevated. IgG depletion of SLE serum A abrogated its nephritis-inducing capacity (Fig. 3B), which suggests that ICs in the sera are required for disease development (Fig. 1A).

FIGURE 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 3.

The pathogenicity of SLE serum correlates with the capacity of hIgG to deposit in the glomeruli. (A) IIA+IIIB+γ−/−Mac-1−/− mice received sera from healthy donors (normal, data are pooled from five donors), six SLE patients (denoted A–F), or heat-aggregated human IgG (ICs). **p < 0.01, ***p < 0.001 compared with mice that received normal sera. Each data point represents one mouse, and the line indicates the median. (B) IIA+IIIB+γ−/−Mac-1−/− mice were treated with SLE sera A subjected to sham or IgG depletion, and urine albumin was determined. (C) Human IgG (hIgG) deposition in glomeruli was quantitated on day 21 in IIA+IIIB+γ−/−Mac-1−/− mice injected with normal human sera, nonpathogenic (D, F) or pathogenic (A, E) SLE sera, or aggregated hIgG (ICs) (n ≥ 3 mice per group). Mean ± SEM is given, and representative pictures of selected samples are shown. *p < 0.05. (D) Glomerular deposition of human IgG isotypes (1–4) was evaluated by immunofluorescence in IIA+IIIB+γ−/−Mac-1−/− given normal or SLE sera A (SLE). Focal tubular basement membrane deposition (arrows) was detected in some cases.

The sera that caused disease, henceforth referred to as pathogenic sera (e.g., SLE sera A and E), were associated with glomerular deposits of human IgG that exhibited a granular pattern characteristic of ICs (Fig. 3C). In contrast, no human IgG deposition was observed when nonpathogenic sera were injected; these included SLE sera D and F and sera from healthy controls (Fig. 3C). All four human IgG isotypes, IgG 1–4, were observed in the glomeruli, predominantly as deposits in the mesangium (Fig. 3D). Specificity of the Abs was confirmed by analyzing their reactivity against purified human IgG1–4 in Western blots (data not shown). In the case of serum A, focal tubular basement membrane deposition of IgG was also detected (Fig. 3D), which is a pattern observed in human lupus nephritis. SLE sera pathogenicity (i.e., capacity of human ICs to deposit in glomeruli) did not correlate with the amount of ICs or IgG present in the sera (Supplemental Table 1A), nor did it correlate with the patient type or lupus manifestations (Supplemental Table 1B).

The susceptibility conferred by Mac-1 deficiency is not due to defects in IgG clearance

Levels of circulating (Fig. 4A) and deposited human IgG-ICs (Fig. 4B) as well as glomerular complement C1q and C3 deposition (Fig. 4B) were comparable between hFcγR-expressing mice that were Mac-1 sufficient (IIA+IIIB+γ−/−) or deficient (IIA+IIIB+γ−/−Mac-1−/−), as were peripheral blood neutrophil and leukocyte counts (Supplemental Table 1C).

FIGURE 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 4.

IC clearance and deposition are similar in susceptible and nonsusceptible mice. (A) Serum was collected from animals at intervals up to day 14 after SLE sera A transfer. Circulating human IgG (hIgG) and human IgG ICs (hICs) were evaluated, and the mean ± SEM were graphed. (B) Kidneys were harvested at day 14 after SLE sera A transfer, and renal sections were stained for hIgG, murine C1q, and complement C3. The mean fluorescence intensity (MFI; average pixel intensity ± SEM) for glomerular hIgG and C3 and the percentage of glomerular area positive for C1q (% area ± SEM) were determined and found to be equivalent in both groups.

Passive transfer of human SLE serum induces arthritis in mice

Notably, two of the pathogenic SLE sera, A (Fig. 5) and E (data not shown), caused arthritis in mice that affected primarily small joints, namely the distal interphalangeal, and were evident at day 4. Patient A had clinical manifestations of arthritis, and patient E did not have arthritis, but presented with Raynaud syndrome. There was no correlation between human symptoms and arthritis development, as some sera from patients who clinically presented with nephritis and arthritis did not induce arthritis in mice (data not shown). Moreover, unlike nephritis, development of arthritis was more variable with different sera samples. As in the case of nephritis, hFcγR-expressing mice lacking Mac-1−/− developed arthritis (Fig. 5A). Histopathological analyses revealed intense joint inflammation with cellular infiltration associated with bone and cartilage destruction (Fig. 5B). Significant deposition of human IgG-IC within synovial blood vessels was observed in both disease-susceptible and nonsusceptible mice (Fig. 5C). Neutrophils were abundant in the lesions (Fig. 5D), whereas macrophages and T cells were not detected (data not shown).

FIGURE 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 5.

Human SLE sera cause arthritis in mice that express hFcγR and lack Mac-1. Mice given SLE sera A were evaluated for the development of arthritis. (A) Inflammation of each limb was assessed, and a clinical score was given, as described in Materials and Methods. As shown in representative pictures, mostly small joint involvement (arrows) was observed. *p < 0.05 compared with IIA+IIIB+γ−/− and IIA+γ−/− given SLE sera. (B) Representative images of histological sections stained with H&E (upper panels) with magnification of boxed area (lower panels) are shown for indicated mice. Bone (b) erosion and inflammatory cell infiltration (*) were apparent only in IIA+IIIB+γ−/−Mac-1−/− mice. The histological score in affected limbs of IIA+IIIB+γ−/−Mac-1−/− and similar digits in IIA+IIIB+γ−/− mice included leukocyte infiltration, synovial thickening, and cartilage and bone erosion. (C) Tissue hIgG staining by immunohistochemistry showed intravascular IC deposition (arrows) in nonsusceptible (upper panel) and susceptible (lower panel) mice treated with SLE sera. (D) Neutrophils in joint sections harvested at indicated days after SLE serum injection were quantitated. Robust neutrophil accumulation was observed only in IIA+IIIB+γ−/−Mac-1−/−. Representative pictures of indicated mice are shown. Only IIA+IIIB+γ−/− Mac1−/− have neutrophil infiltrates (arrow) adjacent to damaged articular surfaces as well as periarticular soft tissue. All data are mean ± SEM. For (B) and (D), *p < 0.05.

Marked glomerular neutrophil infiltration is observed in susceptible mice, whereas macrophages do not contribute to disease

Susceptible mice (hFcγR+γ−/−Mac-1−/−) exhibited abundant glomerular neutrophil infiltration at day 10 that significantly exceeded that in nonsusceptible mice (Fig. 6A). In contrast, a mild interstitial macrophage and T cell infiltration was observed in both groups of mice (Fig. 6A). Thus, Mac-1 deficiency appears to selectively enable neutrophil accumulation. To distinguish whether the Mac-1–expressing cell responsible for resistance to nephritis corresponded to circulating (i.e., monocytes or neutrophils) or resident cells, we generated bone marrow chimeras. Bone marrow from IIAγ−/− or IIAγ−/−Mac-1−/− mice was transferred into lethally irradiated γ−/−Mac-1−/− or γ−/− mice, respectively (i.e., IIAγ−/−→γ−/−Mac-1−/− and IIAγ−/−Mac-1−/−→γ−/−), and 3 mo later SLE serum was administered. IIAγ−/−Mac-1−/− bone marrow provided susceptibility to nephritis when transferred into nonsusceptible γ−/− mice, suggesting that a lack of Mac-1 on hFcγRIIA-expressing circulating cells allows the development of disease (Supplemental Fig. 2A). Immunohistochemistry in tissue of γ−/−Mac1−/− recipients of IIAγ−/− bone marrow revealed Mac-1–positive macrophages in the renal interstitium following human SLE serum transfer, suggesting that SLE serum induces renal infiltration of blood monocytes and their subsequent differentiation into macrophages (Supplemental Fig. 2A). To determine whether monocytes/macrophages contribute to renal injury, these populations were depleted prior to SLE serum transfer by administering clodronate liposomes, which are internalized by these cells and leads to their apoptosis (Supplemental Fig. 2B). Macrophage-depleted IIAγ−/−Mac-1−/− mice remained highly susceptible to nephritis (Fig. 6B), suggesting that macrophages do not significantly contribute to renal injury. Moreover, macrophage depletion in disease-nonsusceptible (IIAγ−/−) mice did not result in proteinuria (Fig. 6C) or glomerular neutrophil infiltration (data not shown) at day 10, suggesting that Mac-1 deficiency in monocytes/macrophages does not enable disease.

FIGURE 6.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 6.

Disease in susceptible mice is associated with neutrophil accumulation; macrophages do not participate in disease development. (A) Kidneys were harvested from mice at day 21 after injection of SLE sera A. Dotted line represents the mean value obtained in susceptible mice given normal human serum and harvested at day 10 (top panel) or day 14 (middle and bottom panels). Neutrophil, macrophage, and T cell infiltration were quantified by immunohistochemistry. Mice treated with anti-GBM serum are included as a positive control for indicated leukocyte infiltration. Mean ± SEM is shown. *p < 0.05, **p < 0.01 compared with IIA+IIIB+γ−/− injected with SLE sera. n = 3–7 mice per group. Animals were treated with liposomes that contained clodronate (+) or PBS (−), and proteinuria was evaluated at indicated times in IIA+γ−/−Mac-1−/− (B) and IIA+γ−/− (C) mice. *p < 0.05. nd, Not determined; ns, not significant.

Mac-1 deficiency modifies the response of neutrophils toward tissue-deposited ICs in vivo

To elucidate the mechanism(s) by which Mac-1 regulates FcγRIIA-mediated neutrophil accumulation, we conducted intravital microscopy of the cremaster muscle that allows the real-time visualization of neutrophil behavior within the vessel wall. The reverse passive Arthus (RPA) reaction, induced by the i.v. administration of soluble BSA and an intrascrotal injection of anti-BSA, results in IC deposition within and outside the cremasteric vessels (13, 28). The RPA induces neutrophil rolling that is P- and E-selectin dependent (28), whereas the slowing of the rolling velocity and adhesion is dependent on murine FcγRs (29) and FcγRIIA (13). Following induction of the RPA, neutrophils in the venules of IIAγ−/−Mac-1−/− mice rolled significantly slower than in IIAγ−/− mice (Fig. 7A). This was not a result of differences between the two groups in expression of LFA-1 on circulating neutrophils or neutrophils recruited to the cremaster (Supplemental Fig. 2C). The slow rolling required FcγRIIA, as it was not observed in γ−/−Mac-1−/− and γ−/− mice (Fig. 7B). The downmodulatory effect of Mac-1 was selective for ICs, as the rolling velocity induced by an intrascrotal injection of TNF-α was actually increased in IIAγ−/−Mac-1−/− mice compared with IIAγ−/− mice (data not shown), as previously described (30). In the RPA, the observed slower neutrophil rolling in IIAγ−/−Mac-1−/− mice was not associated with an increase in the number of adherent cells compared with IIAγ−/− mice (Fig. 7C). E-selectin–mediated activation of LFA-1 has been shown to slow neutrophil rolling velocity, and in turn lead to efficient firm adhesion only in response to a local chemoattractant stimulus, MIP-2 (24). Accordingly, the local microinjection of MIP-2 favored adhesion of neutrophils in IIAγ−/−Mac-1−/− compared with IIAγ−/− animals subjected to the RPA (Fig. 7D). IC induced slow rolling, and MIP-2–induced neutrophil adhesion is most likely LFA-1 dependent, as these steps were markedly diminished in CD18-deficient mice (Fig. 7E, 7F).

FIGURE 7.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 7.

Mac-1 deficiency slows the rolling velocity and increases the chemoattractant-induced adhesion of neutrophils following the RPA reaction. The RPA was induced in the cremaster, and, 3 h later, the mice were prepared for intravital microscopy and neutrophil rolling velocity was measured in hemodynamically similar venules of (A) IIA+γ−/−Mac-1−/− and IIA+γ−/− mice (n = 33 venules in 6 mice per group) and (B) γ−/−Mac-1−/− and γ−/− mice (n = 13 venules in 3 mice per group). Cumulative histograms of rolling velocities are shown. (C) The number of adherent neutrophils in mice analyzed in (A) was determined. (D) Mice were subjected to the RPA, the cremaster was prepared for intravital microscopy, and a local injection of MIP-2 was given as depicted in the diagram. The increase in neutrophil adhesion after local MIP-2 injection (Δ of adherent cells) in IIA+γ−/− and IIA+γ−/−Mac-1−/− mice was calculated (n = 15–16 venules in 6–7 mice per group). (E) Cumulative histogram of neutrophil rolling velocities of WT and CD18−/− mice subjected to the RPA, and (F) Δ of adherent cells upon MIP-2 injection are shown (n = 6 venules in 3 mice per group). For (C), (D), and (F), mean ± SEM are graphed. **p < 0.01, ***p < 0.001.

In summary, FcγRIIA-dependent slow rolling, which correlates with efficient leukocyte adhesion in response to MIP-2, is regulated by Mac-1, with a deficiency in this integrin, resulting in a further decrease in rolling velocity and subsequent enhanced responsiveness of neutrophils to a local chemotactic stimulus.

Discussion

In this study, we show in a novel lupus model that IC deposition and organ damage are not inextricably linked, but that additional genetic factors dictate the propensity for target organ damage. In particular, we demonstrate that the neutrophils’ response to deposited ICs and subsequent tissue injury, following human lupus sera transfer, is modulated by a functional association between an integrin and an IgG receptor. The role of Mac-1 in attenuating FcγRIIA-mediated neutrophil recruitment in the context of deposited ICs is unanticipated from previous work that has established Mac-1 largely as a positive regulator of neutrophil influx and inflammation (8, 31, 32). Our data predict that the R77H Mac-1 variant, which leads to reduced binding to its ligands, may have functional consequences for SLE patients and offer a mechanism by which Mac-1 dysfunction may contribute to end organ injury in SLE.

Disease susceptibility permitted by the absence of Mac-1 was not related to alterations in IC handling presumably by macrophages. Moreover, Mac-1 on macrophages and indeed macrophages themselves did not influence disease susceptibility. Thus, this cell type, abundant in SLE lesions (33), is not essential for target organ injury in our model at least in the time frame of our experiments. Instead, Mac-1 deficiency most likely predisposes to disease development due to unrestrained FcγRIIA-mediated neutrophil accumulation in the kidney. The reported physical interaction of Mac-1 with human FcγRs on the cell surface (34) and the sharing of intracellular ITAM-based signaling cascades by these two receptors (35) led us to the intriguing possibility that Mac-1 on neutrophils, in cis, modulates neutrophil FcγRIIA activity and function.

FcγRIIA on neutrophils clearly has the capacity to induce tissue injury in vivo (13, 14). However, in the context of SLE-IC deposits in the kidney and joints, the regulation of FcγRIIA-mediated neutrophil recruitment appears to be a key step in conferring disease susceptibility. Recent work suggests that binding of FcγRIIA to ICs and FcγRIIA function may be regulated. In vitro, the G protein-coupled receptor agonists C5a and fmlp enhance (14, 36), whereas coengagement of FcγRIIB inhibits (37) FcγRIIA function. How is FcγRIIA regulated by Mac-1? Clues were provided by intravital microscopy. Slowing of the velocity of rolling cells improves their efficiency of firm adhesion (30), and, in the RPA, FcγRIIA plays an important role in mediating slow rolling and leukocyte arrest (13). Additionally, CD18 integrins are required as slow rolling, and MIP-2–mediated adhesion in the RPA is abrogated in CD18-deficient mice. We postulate that FcγRIIA promotes the activation of LFA-1. A deficiency in Mac-1 heightens FcγR activity toward ICs and subsequent LFA-1 activation that in turn leads to further deceleration of the rolling velocity and increased responsiveness to MIP-2. Mac-1 may be responsible for mitigating FcγRIIA-mediated signaling or limiting FcγRIIA mobility or clustering, the molecular details of which require further investigation. Human FcγRIIA appears to functionally interact with murine Mac-1 in cis, suggesting that this interaction uses conserved features of human and mouse Mac-1.

The observed decrease in neutrophil accumulation in Mac-1–deficient mice in other models of IC-mediated disease, including acute anti-GBM, thrombotic glomerulonephritis, and bullous pemphigoid (22, 38, 39), suggests differential roles for Mac-1 in distinct models of IC-based diseases. Complex biological circuits predict dual and sometimes opposing roles for the same receptor that is cell type and context dependent. For example, incomplete phosphorylation of the ITAM following engagement of B or TCRs by low affinity/valency ligands favors inhibitory over activating signaling by these immune receptors (40). Moreover, unsustained FcαRI clustering markedly inhibits, whereas sustained FcαRI aggregation promotes cell activation through differential recruitment of the tyrosine kinase Syk versus an inhibitory protein phosphatase Src homology region 2 domain-containing phosphatase 1 (41, 42). We posit that Mac-1 relays similar context-dependent inhibitory and activating signals, a hypothesis that is supported by the finding that, although the R77H Mac-1 polymorphism is a susceptibility factor for lupus (9), it does not predispose to rheumatoid arthritis (43), another IC-mediated disease. Interestingly, FcγRIIIB may also play context-dependent roles in IC-mediated inflammation. Whereas low expression of FcγRIIIB is associated with SLE (44), high FcγRIIIB levels increase susceptibility to anti-neutrophil cytoplasmic Ab-associated systemic vasculitides, a disease associated with in situ rather than soluble ICs (45, 46). This concept is recapitulated in our mouse models. Human SLE serum-induced nephritis was reduced in mice expressing both human FcγRIIA and FcγRIIIB versus FcγRIIA alone, which contrasts with the greater proteinuria following anti-GBM nephritis in mice expressing both hFcγRs compared with mice expressing FcγRIIA alone (13).

Our studies suggest that neutrophils are the primary cellular link between IgG and target organ damage in our model. Neutrophils are present in renal SLE lesions (47, 48), precede macrophage infiltration (47), and are appreciated as a sign of disease severity (49). Importantly, recent studies identified a subset of neutrophils in SLE patients that synthesize type I IFNs, induce endothelial cell damage (50), release neutrophil extracellular traps that are potentially autoantigenic, and drive IFN-α production by dendritic cells (51, 52). SLE sera transfer results in the development of lesions that recapitulate several features of lupus nephritis. The mice obviously lack the imbalances in the adaptive immune response and therefore chronicity of the disease. However, like SLE patients, in which development of lupus nephritis is not associated with autoantibodies of singular IgG specificity (53) a spectrum of IgG1–4 subtypes was found deposited in the glomerulus with the capacity of SLE sera to induce proteinuria being directly correlated with their ability to deposit in the glomerulus. Histological features similar to human disease include mesangial hypercellularity and mesangial deposits (mainly IgG), C3 deposition, endocapillary and extracapillary proliferation (crescents), and neutrophils. The lack of the interstitial component, thickening of the membrane or podocyte effacement, is likely because the immune deregulation in SLE patients is much more profound than in our model. Renal injury in our model is unlikely a consequence simply of an immune response against heterologous human IgG, as normal human serum, some SLE-patient serum, and heat-aggregated human IgG failed to induce nephritis and murine anti-human IgG Ab deposition in the glomeruli was not significant.

Indiscriminate immunosuppression remains the prevailing therapy in SLE with significant toxicity, and the expectations from therapeutic targeting of the aberrant immune system have remained unfulfilled (4). Our data in a humanized mouse model indicate that deposition of circulating autoantibodies is not sufficient for target organ damage. Rather, regulation of neutrophil FcγRIIA by Mac-1 fundamentally influences IC-mediated end organ damage. Moreover, our humanized passive SLE sera transfer model will aid in delineating additional mechanisms specifically driving lupus-induced tissue injury and serve as a preclinical platform to test new therapeutics targeted at preventing lupus end organ damage.

Disclosures

The authors have no financial conflicts of interest.

Acknowledgments

We thank Dr. Isaac Stillman (Beth Israel Deaconess Medical Center, Boston, MA) for help in histologic interpretations, Dr. Klaus Ley (La Jolla Institute for Allergy and Immunology, La Jolla, CA) for technical advice in intravital microscopy, and Lorna Andersson, Elizabeth Thayer, and Lina Du (Brigham and Women’s Hospital, Boston, MA) for technical assistance.

Footnotes

  • This work was supported by National Institutes of Health Grants RO1 HL065095 and AR050800 (to T.N.M.), AI42269 (to G.C.T.), and K23 AR055672 (to V.C.K.); a Target Identification in Lupus Grant/Alliance for Lupus Research Foundation (to T.N.M.); Consejo Nacional de Ciencia y Tecnologia and Fundación México en Harvard (to F.R.); the Arthritis Foundation (to N.T.); Japan Society for the Promotion of Science Postdoctoral Fellowship for Research Abroad (to H.N.); and the Novartis Foundation (to T.E.).

  • The online version of this article contains supplemental material.

  • Abbreviations used in this article:

    GBM
    glomerular basement membrane
    hFcγR
    human FcγR
    IC
    immune complex
    RPA
    reverse passive Arthus
    SLE
    systemic lupus erythematosus
    WT
    wild-type.

  • Received June 11, 2012.
  • Accepted August 4, 2012.
  • Copyright © 2012 by The American Association of Immunologists, Inc.

References

  1. ↵
    1. Arbuckle M. R.,
    2. M. T. McClain,
    3. M. V. Rubertone,
    4. R. H. Scofield,
    5. G. J. Dennis,
    6. J. A. James,
    7. J. B. Harley
    . 2003. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med. 349: 1526–1533.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Schmidt R. E.,
    2. J. E. Gessner
    . 2005. Fc receptors and their interaction with complement in autoimmunity. Immunol. Lett. 100: 56–67.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Ravetch J. V.,
    2. S. Bolland
    . 2001. IgG Fc receptors. Annu. Rev. Immunol. 19: 275–290.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Wu T.,
    2. C. Mohan
    . 2007. Three pathogenic determinants in immune nephritis: anti-glomerular antibody specificity, innate triggers and host genetics. Front. Biosci. 12: 2207–2211.
    OpenUrlCrossRefPubMed
    1. Bagavant H.,
    2. S. M. Fu
    . 2005. New insights from murine lupus: disassociation of autoimmunity and end organ damage and the role of T cells. Curr. Opin. Rheumatol. 17: 523–528.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Nguyen C.,
    2. N. Limaye,
    3. E. K. Wakeland
    . 2002. Susceptibility genes in the pathogenesis of murine lupus. Arthritis Res. 4(Suppl. 3): S255–S263.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Crispín J. C.,
    2. S. N. Liossis,
    3. K. Kis-Toth,
    4. L. A. Lieberman,
    5. V. C. Kyttaris,
    6. Y. T. Juang,
    7. G. C. Tsokos
    . 2010. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol. Med. 16: 47–57.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Ehlers M. R.
    2000. CR3: a general purpose adhesion-recognition receptor essential for innate immunity. Microbes Infect. 2: 289–294.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Nath S. K.,
    2. S. Han,
    3. X. Kim-Howard,
    4. J. A. Kelly,
    5. P. Viswanathan,
    6. G. S. Gilkeson,
    7. W. Chen,
    8. C. Zhu,
    9. R. P. McEver,
    10. R. P. Kimberly,
    11. et al
    . 2008. A nonsynonymous functional variant in integrin-alpha(M) (encoded by ITGAM) is associated with systemic lupus erythematosus. Nat. Genet. 40: 152–154.
    OpenUrlCrossRefPubMed
  9. ↵
    1. MacPherson M.,
    2. H. S. Lek,
    3. A. Prescott,
    4. S. C. Fagerholm
    2011. A systemic lupus erythematosus-associated R77H substitution in the CDIIb chain of Mac-1 integrin compromises leukocyte adhesion and phagocytosis. J. Biol. Chem. 286: 17303–17310.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Hogarth P. M.
    2002. Fc receptors are major mediators of antibody based inflammation in autoimmunity. Curr. Opin. Immunol. 14: 798–802.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Mayadas T. N.,
    2. G. C. Tsokos,
    3. N. Tsuboi
    . 2009. Mechanisms of immune complex-mediated neutrophil recruitment and tissue injury. Circulation 120: 2012–2024.
    OpenUrlFREE Full Text
  12. ↵
    1. Tsuboi N.,
    2. K. Asano,
    3. M. Lauterbach,
    4. T. N. Mayadas
    . 2008. Human neutrophil Fcgamma receptors initiate and play specialized nonredundant roles in antibody-mediated inflammatory diseases. Immunity 28: 833–846.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Tsuboi N.,
    2. T. Ernandez,
    3. X. Li,
    4. H. Nishi,
    5. X. Cullere,
    6. D. Mekala,
    7. M. Hazen,
    8. J. Köhl,
    9. D. M. Lee,
    10. T. N. Mayadas
    . 2011. Regulation of human neutrophil Fcγ receptor IIa by C5a receptor promotes inflammatory arthritis in mice. Arthritis Rheum. 63: 467–478.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Takai T.,
    2. M. Li,
    3. D. Sylvestre,
    4. R. Clynes,
    5. J. V. Ravetch
    . 1994. FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell 76: 519–529.
    OpenUrlCrossRefPubMed
    1. Coxon A.,
    2. P. Rieu,
    3. F. J. Barkalow,
    4. S. Askari,
    5. A. H. Sharpe,
    6. U. H. von Andrian,
    7. M. A. Arnaout,
    8. T. N. Mayadas
    . 1996. A novel role for the beta 2 integrin CD11b/CD18 in neutrophil apoptosis: a homeostatic mechanism in inflammation. Immunity 5: 653–666.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Scharffetter-Kochanek K.,
    2. H. Lu,
    3. K. Norman,
    4. N. van Nood,
    5. F. Munoz,
    6. S. Grabbe,
    7. M. McArthur,
    8. I. Lorenzo,
    9. S. Kaplan,
    10. K. Ley,
    11. et al
    . 1998. Spontaneous skin ulceration and defective T cell function in CD18 null mice. J. Exp. Med. 188: 119–131.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Rosenkranz A. R.,
    2. D. L. Mendrick,
    3. R. S. Cotran,
    4. T. N. Mayadas
    . 1999. P-selectin deficiency exacerbates experimental glomerulonephritis: a protective role for endothelial P-selectin in inflammation. J. Clin. Invest. 103: 649–659.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Baharav E.,
    2. S. Bar-Yehuda,
    3. L. Madi,
    4. D. Silberman,
    5. L. Rath-Wolfson,
    6. M. Halpren,
    7. A. Ochaion,
    8. A. Weinberger,
    9. P. Fishman
    . 2005. Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models. J. Rheumatol. 32: 469–476.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Duffau P.,
    2. J. Seneschal,
    3. C. Nicco,
    4. C. Richez,
    5. E. Lazaro,
    6. I. Douchet,
    7. C. Bordes,
    8. J. F. Viallard,
    9. C. Goulvestre,
    10. J. L. Pellegrin,
    11. et al
    . 2010. Platelet CD154 potentiates interferon-alpha secretion by plasmacytoid dendritic cells in systemic lupus erythematosus. Sci. Transl. Med. 2: 47ra63.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Chen M.,
    2. E. Boilard,
    3. P. A. Nigrovic,
    4. P. Clark,
    5. D. Xu,
    6. G. A. Fitzgerald,
    7. L. P. Audoly,
    8. D. M. Lee
    . 2008. Predominance of cyclooxygenase 1 over cyclooxygenase 2 in the generation of proinflammatory prostaglandins in autoantibody-driven K/B×N serum-transfer arthritis. Arthritis Rheum. 58: 1354–1365.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Tang T.,
    2. A. Rosenkranz,
    3. K. J. Assmann,
    4. M. J. Goodman,
    5. J. C. Gutierrez-Ramos,
    6. M. C. Carroll,
    7. R. S. Cotran,
    8. T. N. Mayadas
    . 1997. A role for Mac-1 (CDIIb/CD18) in immune complex-stimulated neutrophil function in vivo: Mac-1 deficiency abrogates sustained Fcgamma receptor-dependent neutrophil adhesion and complement-dependent proteinuria in acute glomerulonephritis. J. Exp. Med. 186: 1853–1863.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Van Rooijen N.,
    2. A. Sanders
    . 1994. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J. Immunol. Methods 174: 83–93.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Ley K.,
    2. M. Allietta,
    3. D. C. Bullard,
    4. S. Morgan
    . 1998. Importance of E-selectin for firm leukocyte adhesion in vivo. Circ. Res. 83: 287–294.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Fu Y.,
    2. Y. Du,
    3. C. Mohan
    . 2007. Experimental anti-GBM disease as a tool for studying spontaneous lupus nephritis. Clin. Immunol. 124: 109–118.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Rosenkranz A. R.,
    2. S. Knight,
    3. S. Sethi,
    4. S. I. Alexander,
    5. R. S. Cotran,
    6. T. N. Mayadas
    . 2000. Regulatory interactions of alphabeta and gammadelta T cells in glomerulonephritis. Kidney Int. 58: 1055–1066.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Billiau A.,
    2. P. Matthys
    . 2001. Modes of action of Freund’s adjuvants in experimental models of autoimmune diseases. J. Leukoc. Biol. 70: 849–860.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Norman M. U.,
    2. N. C. Van De Velde,
    3. J. R. Timoshanko,
    4. A. Issekutz,
    5. M. J. Hickey
    . 2003. Overlapping roles of endothelial selectins and vascular cell adhesion molecule-1 in immune complex-induced leukocyte recruitment in the cremasteric microvasculature. Am. J. Pathol. 163: 1491–1503.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Stokol T.,
    2. P. O’Donnell,
    3. L. Xiao,
    4. S. Knight,
    5. G. Stavrakis,
    6. M. Botto,
    7. U. H. von Andrian,
    8. T. N. Mayadas
    . 2004. C1q governs deposition of circulating immune complexes and leukocyte Fcgamma receptors mediate subsequent neutrophil recruitment. J. Exp. Med. 200: 835–846.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. Dunne J. L.,
    2. C. M. Ballantyne,
    3. A. L. Beaudet,
    4. K. Ley
    . 2002. Control of leukocyte rolling velocity in TNF-alpha-induced inflammation by LFA-1 and Mac-1. Blood 99: 336–341.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. Jones S. L.,
    2. E. J. Brown
    . 1996. Functional cooperation between Fcg receptors and complement receptors in phagocytes. In Human IgG Fc Receptors. van de Winkel J. G. J., P. J. A. Capel, eds. R.G. Landes Company, Austin, TX, p. 149–163.
  30. ↵
    1. Li X.,
    2. A. Utomo,
    3. X. Cullere,
    4. M. M. Choi,
    5. D. A. Milner Jr..,
    6. D. Venkatesh,
    7. S. H. Yun,
    8. T. N. Mayadas
    . 2011. The β-glucan receptor Dectin-1 activates the integrin Mac-1 in neutrophils via Vav protein signaling to promote Candida albicans clearance. Cell Host Microbe 10: 603–615.
    OpenUrlCrossRefPubMed
  31. ↵
    1. Li Y.,
    2. P. Y. Lee,
    3. W. H. Reeves
    . 2010. Monocyte and macrophage abnormalities in systemic lupus erythematosus. Arch. Immunol. Ther. Exp. 58: 355–364.
    OpenUrlCrossRef
  32. ↵
    1. Petty H. R.,
    2. R. G. Worth,
    3. R. F. Todd III.
    . 2002. Interactions of integrins with their partner proteins in leukocyte membranes. Immunol. Res. 25: 75–95.
    OpenUrlCrossRefPubMed
  33. ↵
    1. Mócsai A.,
    2. C. L. Abram,
    3. Z. Jakus,
    4. Y. Hu,
    5. L. L. Lanier,
    6. C. A. Lowell
    . 2006. Integrin signaling in neutrophils and macrophages uses adaptors containing immunoreceptor tyrosine-based activation motifs. Nat. Immunol. 7: 1326–1333.
    OpenUrlCrossRefPubMed
  34. ↵
    1. Nagarajan S.,
    2. K. Venkiteswaran,
    3. M. Anderson,
    4. U. Sayed,
    5. C. Zhu,
    6. P. Selvaraj
    . 2000. Cell-specific, activation-dependent regulation of neutrophil CD32A ligand-binding function. Blood 95: 1069–1077.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. Syam S.,
    2. P. Mero,
    3. T. Pham,
    4. C. A. McIntosh,
    5. P. Bruhns,
    6. J. W. Booth
    . 2010. Differential recruitment of activating and inhibitory Fc gamma RII during phagocytosis. J. Immunol. 184: 2966–2973.
    OpenUrlAbstract/FREE Full Text
  36. ↵
    1. Liu Z.,
    2. M. Zhao,
    3. N. Li,
    4. L. A. Diaz,
    5. T. N. Mayadas
    . 2006. Differential roles for beta2 integrins in experimental autoimmune bullous pemphigoid. Blood 107: 1063–1069.
    OpenUrlAbstract/FREE Full Text
  37. ↵
    1. Hirahashi J.,
    2. K. Hishikawa,
    3. S. Kaname,
    4. N. Tsuboi,
    5. Y. Wang,
    6. D. I. Simon,
    7. G. Stavrakis,
    8. T. Shimosawa,
    9. L. Xiao,
    10. Y. Nagahama,
    11. et al
    . 2009. Mac-1 (CD11b/CD18) links inflammation and thrombosis after glomerular injury. Circulation 120: 1255–1265.
    OpenUrlAbstract/FREE Full Text
  38. ↵
    1. Waterman P. M.,
    2. J. C. Cambier
    . 2010. The conundrum of inhibitory signaling by ITAM-containing immunoreceptors: potential molecular mechanisms. FEBS Lett. 584: 4878–4882.
    OpenUrlCrossRefPubMed
  39. ↵
    1. Pasquier B.,
    2. P. Launay,
    3. Y. Kanamaru,
    4. I. C. Moura,
    5. S. Pfirsch,
    6. C. Ruffié,
    7. D. Hénin,
    8. M. Benhamou,
    9. M. Pretolani,
    10. U. Blank,
    11. R. C. Monteiro
    . 2005. Identification of FcalphaRI as an inhibitory receptor that controls inflammation: dual role of FcRgamma ITAM. Immunity 22: 31–42.
    OpenUrlPubMed
  40. ↵
    1. Kanamaru Y.,
    2. S. Pfirsch,
    3. M. Aloulou,
    4. F. Vrtovsnik,
    5. M. Essig,
    6. C. Loirat,
    7. G. Deschênes,
    8. C. Guérin-Marchand,
    9. U. Blank,
    10. R. C. Monteiro
    . 2008. Inhibitory ITAM signaling by Fc alpha RI-FcR gamma chain controls multiple activating responses and prevents renal inflammation. J. Immunol. 180: 2669–2678.
    OpenUrlAbstract/FREE Full Text
  41. ↵
    1. Phipps-Green A. J.,
    2. R. K. Topless,
    3. M. E. Merriman,
    4. N. Dalbeth,
    5. P. J. Gow,
    6. A. A. Harrison,
    7. J. Highton,
    8. P. B. Jones,
    9. L. K. Stamp,
    10. P. Harrison,
    11. et al
    . 2009. No evidence for association of the systemic lupus erythematosus-associated ITGAM variant, R77H, with rheumatoid arthritis in the Caucasian population. Rheumatology 48: 1614–1615.
    OpenUrlFREE Full Text
  42. ↵
    1. Niederer H. A.,
    2. M. R. Clatworthy,
    3. L. C. Willcocks,
    4. K. G. C. Smith
    . 2010. FcγRIIB, FcγRIIIB, and systemic lupus erythematosus. Ann. N. Y. Acad. Sci. 1183: 69–88.
    OpenUrlCrossRefPubMed
  43. ↵
    1. Aitman T. J.,
    2. R. Dong,
    3. T. J. Vyse,
    4. P. J. Norsworthy,
    5. M. D. Johnson,
    6. J. Smith,
    7. J. Mangion,
    8. C. Roberton-Lowe,
    9. A. J. Marshall,
    10. E. Petretto,
    11. et al
    . 2006. Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans. Nature 439: 851–855.
    OpenUrlCrossRefPubMed
  44. ↵
    1. Willcocks L. C.,
    2. P. A. Lyons,
    3. M. R. Clatworthy,
    4. J. I. Robinson,
    5. W. Yang,
    6. S. A. Newland,
    7. V. Plagnol,
    8. N. N. McGovern,
    9. A. M. Condliffe,
    10. E. R. Chilvers,
    11. et al
    . 2008. Copy number of FCGR3B, which is associated with systemic lupus erythematosus, correlates with protein expression and immune complex uptake. J. Exp. Med. 205: 1573–1582.
    OpenUrlAbstract/FREE Full Text
  45. ↵
    1. Segerer S.,
    2. A. Henger,
    3. H. Schmid,
    4. M. Kretzler,
    5. D. Draganovici,
    6. U. Brandt,
    7. E. Noessner,
    8. P. J. Nelson,
    9. D. Kerjaschki,
    10. D. Schlöndorff,
    11. H. Regele
    . 2006. Expression of the chemokine receptor CXCR1 in human glomerular diseases. Kidney Int. 69: 1765–1773.
    OpenUrlCrossRefPubMed
  46. ↵
    1. Mayadas T. N.,
    2. F. Rosetti,
    3. T. Ernandez,
    4. S. Sethi
    . 2010. Neutrophils: game changers in glomerulonephritis? Trends Mol. Med. 16: 368–378.
    OpenUrlCrossRefPubMed
  47. ↵
    Molad, Y., and B. N. Cronstein. 2007. Neutrophils (polymorphonuclear leukocytes) in systemic lupus erythematosus. In Systemic Lupus Erythematosus: a Companion to Rheumatology. G. C. Tsokos and J. S. Smolen, eds. Mosby, Philadelphia, PA, pp. 281–286.
  48. ↵
    1. Denny M. F.,
    2. S. Yalavarthi,
    3. W. Zhao,
    4. S. G. Thacker,
    5. M. Anderson,
    6. A. R. Sandy,
    7. W. J. McCune,
    8. M. J. Kaplan
    . 2010. A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs. J. Immunol. 184: 3284–3297.
    OpenUrlAbstract/FREE Full Text
  49. ↵
    1. Garcia-Romo G. S.,
    2. S. Caielli,
    3. B. Vega,
    4. J. Connolly,
    5. F. Allantaz,
    6. Z. Xu,
    7. M. Punaro,
    8. J. Baisch,
    9. C. Guiducci,
    10. R. L. Coffman,
    11. et al
    . 2011. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci. Transl. Med. 3: 73ra20.
    OpenUrlAbstract/FREE Full Text
  50. ↵
    1. Lande R.,
    2. D. Ganguly,
    3. V. Facchinetti,
    4. L. Frasca,
    5. C. Conrad,
    6. J. Gregorio,
    7. S. Meller,
    8. G. Chamilos,
    9. R. Sebasigari,
    10. V. Riccieri,
    11. et al
    . 2011. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci. Transl. Med. 3: 73ra19.
    OpenUrlAbstract/FREE Full Text
  51. ↵
    1. Bagavant H.,
    2. S. M. Fu
    . 2009. Pathogenesis of kidney disease in systemic lupus erythematosus. Curr. Opin. Rheumatol. 21: 489–494.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

The Journal of Immunology: 189 (7)
The Journal of Immunology
Vol. 189, Issue 7
1 Oct 2012
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Advertising (PDF)
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Immunology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Human Lupus Serum Induces Neutrophil-Mediated Organ Damage in Mice That Is Enabled by Mac-1 Deficiency
(Your Name) has forwarded a page to you from The Journal of Immunology
(Your Name) thought you would like to see this page from the The Journal of Immunology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Human Lupus Serum Induces Neutrophil-Mediated Organ Damage in Mice That Is Enabled by Mac-1 Deficiency
Florencia Rosetti, Naotake Tsuboi, Kan Chen, Hiroshi Nishi, Thomas Ernandez, Sanjeev Sethi, Kevin Croce, George Stavrakis, Jorge Alcocer-Varela, Diana Gómez-Martin, Nico van Rooijen, Vasileios C. Kyttaris, Andrew H. Lichtman, George C. Tsokos, Tanya N. Mayadas
The Journal of Immunology October 1, 2012, 189 (7) 3714-3723; DOI: 10.4049/jimmunol.1201594

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Human Lupus Serum Induces Neutrophil-Mediated Organ Damage in Mice That Is Enabled by Mac-1 Deficiency
Florencia Rosetti, Naotake Tsuboi, Kan Chen, Hiroshi Nishi, Thomas Ernandez, Sanjeev Sethi, Kevin Croce, George Stavrakis, Jorge Alcocer-Varela, Diana Gómez-Martin, Nico van Rooijen, Vasileios C. Kyttaris, Andrew H. Lichtman, George C. Tsokos, Tanya N. Mayadas
The Journal of Immunology October 1, 2012, 189 (7) 3714-3723; DOI: 10.4049/jimmunol.1201594
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosures
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Anti-inflammatory activity of Dioscoreae rhizome in macrophages by inhibition of pro-inflammatory cytokines via NF-κB signaling pathway (54.11)
  • Lung dysfunction in a mouse model of inflammation is dependent on T-cell-independent IL-13 expression (54.18)
  • TSG-6, a new protein ligand for CXCL8, modulates the activity of this pro-inflammatory chemokine (54.12)
Show more INFLAMMATION

Similar Articles

Navigate

  • Home
  • Current Issue
  • Next in The JI
  • Archive
  • Brief Reviews
  • Pillars of Immunology
  • Translating Immunology

For Authors

  • Submit a Manuscript
  • Instructions for Authors
  • About the Journal
  • Journal Policies
  • Editors

General Information

  • Advertisers
  • Subscribers
  • Rights and Permissions
  • Accessibility Statement
  • FAR 889
  • Privacy Policy
  • Disclaimer

Journal Services

  • Email Alerts
  • RSS Feeds
  • ImmunoCasts
  • Twitter

Copyright © 2022 by The American Association of Immunologists, Inc.

Print ISSN 0022-1767        Online ISSN 1550-6606